South Africa Releases New Standards for E-cigarette Products

Oct.21.2024
South Africa Releases New Standards for E-cigarette Products
SABS releases e-cigarette product standards in South Africa to ensure safety and quality, VPASA CEO highlights milestone.

According to a report by IOL on October 19th, the South African Bureau of Standards (SABS) has officially released e-cigarette product standards.


According to Asanda Gcoyi, CEO of the Vapour Product Association of South Africa (VPASA), this marks an important milestone for manufacturers and consumers. The new standard can now be purchased through the South African Bureau of Standards, which provides comprehensive guidelines to ensure the consistency, safety, and quality of e-cigarette products in the market. This standard covers key elements such as production, packaging, labeling, and testing specifications, as well as regulations on the ingredients of e-cigarette liquids.


One prominent feature is setting the nicotine content limit at 35%. Goy emphasizes the importance of this regulation, stating, "Our commitment to consumer safety is paramount. Implementing a nicotine content limit will align South Africa's e-cigarette market with international standards to protect consumers from the potential harm of excessive nicotine concentrations.


Although adherence to these guidelines is voluntary, Goy is calling on all stakeholders to comply and emphasizes the importance of consumer protection laws, which require stakeholders to align their products with established standards. Goy added, "These standards will help consumers make informed choices about the e-cigarette products they use, ensuring that products following the SABS guidelines are designed with consumer safety in mind.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24
Isle of Wight councillors raise concerns about youth vaping; one says it may be seen “akin to asbestos”
Isle of Wight councillors raise concerns about youth vaping; one says it may be seen “akin to asbestos”
Concerns about the effects of vaping on young people and public health were raised at County Hall, the report said, with Cllr Chris Jarman saying it may one day be viewed as “akin to asbestos.” Jarman cited NHS-related research and a case highlighted by Hull University Teaching Hospitals NHS Trust: a 15-year-old admitted with chest pain and breathing difficulty who reported cannabis use and vaping about 500 puffs per day and was diagnosed via CT with “air leak syndrome.”
Feb.27 by 2FIRSTS.ai
Philippine Tobacco Control Coalition Backs Raising Legal Age for Vape and Tobacco Products to 25
Philippine Tobacco Control Coalition Backs Raising Legal Age for Vape and Tobacco Products to 25
A coalition of health and child rights advocates in the Philippines said it supports Health Secretary Teodoro Herbosa’s call to raise the legal age restriction for vape and tobacco products from 18 to 25. The group said scientific evidence shows that the brain of a young person continues to develop until the mid-20s, and that nicotine exposure during that period can cause lasting impairment in impulse control, learning, and mood regulation.
Mar.11 by 2FIRSTS.ai
Smoore International Reports 2025 Revenue of RMB 14.256 Billion, Up 20.8%
Smoore International Reports 2025 Revenue of RMB 14.256 Billion, Up 20.8%
On March 17, Smoore International Holdings Limited released its annual results for the year ended December 31, 2025. Revenue reached RMB 14.256 billion, up 20.8% year on year. Gross profit was RMB 4.857 billion, with a gross margin of 34.1%. Profit for the year was RMB 1.062 billion, down 18.5%, while adjusted profit for the year was RMB 1.530 billion, up 1.3%. By segment, revenue from enterprise customers was RMB 11.344 billion and revenue from own-brand business was RMB 2.912 billion.
Mar.18 by 2FIRSTS.ai
Ispire Q2 FY2026 revenue falls to $20.3M as it trims lower-quality customers; A/R down nearly 20%
Ispire Q2 FY2026 revenue falls to $20.3M as it trims lower-quality customers; A/R down nearly 20%
Ispire reported a sharp year-on-year revenue decline in Q2 FY2026 as it shifted away from lower-quality customers, while cutting operating expenses and narrowing its net loss. The company also highlighted improved collections, with net accounts receivable down nearly one-fifth since June 30, 2025, alongside ongoing manufacturing and technology initiatives.
Feb.09 by 2FIRSTS.ai
Five Inner West Sydney shops shut for 90 days after 780,000 illicit cigarettes and 2,200 illegal vapes seized
Five Inner West Sydney shops shut for 90 days after 780,000 illicit cigarettes and 2,200 illegal vapes seized
NSW Health has shut down five Inner West Sydney stores for 90 days after a major seizure of illicit cigarettes and illegal vapes, with two additional premises in Northern NSW also served closure notices. The action forms part of a broader crackdown that has seen 66 stores closed since new laws took effect in late 2025, with NSW Health warning further enforcement — including prosecution — may follow.
Feb.09 by 2FIRSTS.ai